Vericel Corp. VCEL

What this company does

Vericel Corporation markets two U.S. Food and Drug Administration approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. It operates a cell manufacturing facility in Cambridge, Massachusetts, currently used for U.S. manufacturing and distribution of MACI and Epicel. As of December 31, 2025, the company employed approximately 398 full-time employees. MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement Humanitarian Use Device indicated for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of a patient's total body surface area. It holds an exclusive license from MediWound Ltd. for the North American rights to NexoBrid, a topically-administered biological orphan product containing proteolytic enzymes indicated for the removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Written from the business description in VERICEL CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.